Benjamin Ebert is the recipient of the Erasmus Hematology Award 2025. The Erasmus Hematology Award has been established to honor a distinguished scientist who has made pivotal contributions to our understanding in an area of Hematology.
The official ceremony and the Hematology Award lecture took place during the Erasmus MC Cancer Retreat, at the SS Rotterdam on Thursday 3 April. The title of Dr Ebert’s lecture was “Malignant and non-malignant consequences of precancerous states”.
Benjamin Ebert
Dr Benjamin L. Ebert is currently president and CEO of Dana-Farber Cancer Institute, director of Dana-Farber/Harvard Cancer Center, and is the Richard and Susan Smith Professor of Medicine at Harvard Medical School. He is a world leading expert in hematology and his research focuses on the molecular basis and treatment of hematologic malignancies and its non-malignant precursor conditions, with a particular focus on myelodysplastic syndromes (MDS). His landmark studies of the genetic origins of MDS led to the characterization of clonal hematopoiesis of indeterminate potential (CHIP). Dr Ebert and his group showed in subsequent studies that this pre-malignant state increases not only the risk of hematological and solid cancers, but also the risk of cardiovascular disease and other inflammatory diseases.
Dr Ebert is handed the Hematology Award by Dr Leebeek, Head of the Department of Hematology
Reactie plaatsen
Reacties